Tag:

Takeda Pharmaceutical

Latest Headlines

Latest Headlines

BioXcel adds Takeda to its roster of A-list clients

BioXcel has added another big name to its list of clients. Takeda is the latest company to sign up to work with BioXcel, a database-driven drug discovery shop that already boasts relationships with Alexion, Sanofi, Teva and Vertex.

AZ's Onglyza has most to lose at FDA safety confab, analysts say

FDA experts will grill a couple of diabetes meds next Tuesday, and the outcome of that debate could put a damper on sales. The drugs: AstraZeneca's Onglyza and Takeda's Nesina, both DPP-4 blood sugar-fighters. The questions: Do they really increase the risk of heart failure? And if so, what's to be done about it?

Takeda looks to settle thousands of Actos U.S. lawsuits for $2B

Takeda Pharmaceutical has offered $2.2 billion to settle all U.S. claims linked to its diabetes drug Actos as it battles thousands of cases and stretches legal resources even with some verdicts favorable, a report said April 1.

Infinity pulls trigger on Takeda oncology candidate option

Infinity Pharmaceuticals exercised an option this week to purchase worldwide royalty obligations ranging from 7% to 11% on sales of duvelisib (IPI-145) in oncology indications from Takeda Pharmaceutical for $52.5 million.

Busy Takeda transfers HPV vaccine candidate to research institute for development

Takeda Pharmaceutical said it has done its job and is bowing out of further development of a human papillomavirus vaccine.

Takeda touts CV data from alogliptin use in high-risk diabetes patients

Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.

UPDATE: Takeda confirms eyeing opportunities in India, elsewhere, in vaccine space

Japan's Takeda Pharmaceutical has looked at Indian companies in the vaccine space as it moves to tighten focus on that aspect of its business ahead of a Phase III trial for a dengue candidate and more broadly emerging markets as seen by a recent M&A deal in Turkey.

Pennsylvania jury finds against Takeda in Actos lawsuit for $1.3 million in damages

It took a U.S. jury only two hours to decide to assess Takeda Pharmaceutical $1.3 million in punitive damages for the bladder cancer it ruled earlier were caused by Actos (pioglitazone) diabetes drug. 

Takeda's U.S. chief bows out amid management shake-up

When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.

Contrave demand swamps Takeda's direct-delivery discount program

Private insurers and public payers have refused to cover obesity drugs--or foisted big copays onto patients--dragging down new drugs. So, when Takeda rolled out Orexigen's new obesity drug Contrave a few weeks ago, the Japanese drugmaker also rolled out a direct-delivery program, Direct Save.